Share on StockTwits

Synageva BioPharma Corp (NASDAQ:GEVA)‘s stock had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday. They currently have a $110.00 price objective on the stock, down from their previous price objective of $115.00. JPMorgan Chase & Co.’s target price would indicate a potential upside of 4.96% from the company’s current price.

In other Synageva BioPharma Corp news, Director Barry D. Quart sold 1,375 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $100.00, for a total transaction of $137,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of other analysts have also recently weighed in on GEVA. Analysts at Citigroup Inc. initiated coverage on shares of Synageva BioPharma Corp in a research note on Tuesday. They set a “neutral” rating and a $113.00 price target on the stock. Separately, analysts at Leerink Swann reiterated a “market perform” rating on shares of Synageva BioPharma Corp in a research note on Thursday, May 15th. They now have a $89.00 price target on the stock, down previously from $101.00. Finally, analysts at Nomura cut their price target on shares of Synageva BioPharma Corp from $144.00 to $140.00 in a research note on Thursday, May 1st. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Synageva BioPharma Corp presently has a consensus rating of “Buy” and an average target price of $108.88.

Shares of Synageva BioPharma Corp (NASDAQ:GEVA) traded down 14.32% on Tuesday, hitting $89.79. 660,785 shares of the company’s stock traded hands. Synageva BioPharma Corp has a 52 week low of $42.79 and a 52 week high of $119.42. The stock has a 50-day moving average of $87.30 and a 200-day moving average of $86.67. The company’s market cap is $2.965 billion.

Synageva BioPharma Corp (NASDAQ:GEVA) last announced its earnings results on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. On average, analysts predict that Synageva BioPharma Corp will post $-5.93 earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.